28 reports of this reaction
2.1% of all METHYLERGONOVINE MALEATE reports
#9 most reported adverse reaction
HAEMORRHAGE is the #9 most commonly reported adverse reaction for METHYLERGONOVINE MALEATE, manufactured by Lupin Pharmaceuticals,Inc.. There are 28 FDA adverse event reports linking METHYLERGONOVINE MALEATE to HAEMORRHAGE. This represents approximately 2.1% of all 1,362 adverse event reports for this drug.
Patients taking METHYLERGONOVINE MALEATE who experience haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMORRHAGE is a less commonly reported adverse event for METHYLERGONOVINE MALEATE, but still significant enough to appear in the safety profile.
In addition to haemorrhage, the following adverse reactions have been reported for METHYLERGONOVINE MALEATE:
The following drugs have also been linked to haemorrhage in FDA adverse event reports:
HAEMORRHAGE has been reported as an adverse event in 28 FDA reports for METHYLERGONOVINE MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMORRHAGE accounts for approximately 2.1% of all adverse event reports for METHYLERGONOVINE MALEATE, making it a notable side effect.
If you experience haemorrhage while taking METHYLERGONOVINE MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.